GlassScriptPhysician profile
Raed Al-Dallow
NPI 1164572095
$19,352.36
in general payments reported to CMS, 2019-2025
31 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,217 · 2020: $7,051 · 2021: $210 · 2022: $1,116 · 2023: $212 · 2024: $1,389 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497 · Travel and Lodging: $241 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.10 |
| Travel and Lodging | $241.03 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13,950.05 | 2019-2025 | Watchman Access System, Avvigo Guidance System, Emerge Push |
| Abiomed | $1,414.09 | 2019-2025 | Impella |
| Abbott Laboratories | $683.65 | 2019-2022 | |
| Medtronic Vascular, INC. | $345.99 | 2019-2020 | |
| Medicure Pharma INC. | $300.00 | 2020 | |
| Biosense Webster, INC. | $246.38 | 2025 | Carto 3, Nuvision Ice Catheter |
| Janssen Pharmaceuticals, INC | $237.95 | 2019-2023 | Xarelto |
| Cvrx, INC. | $188.79 | 2024-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $187.91 | 2019-2024 | Camzyos |
| Livanova USA, INC. | $162.60 | 2019-2020 | |
| Amgen INC. | $155.41 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.78 | 2019-2025 | Jardiance |
| Pfizer INC. | $137.78 | 2019-2024 | |
| Cook Medical LLC | $131.96 | 2019-2024 | Rosen |
| W. L. Gore & Associates, INC. | $131.84 | 2022-2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $126.67 | 2022-2025 | In.Pact Admiral, Onyx Frontier, Launcher |
| Penumbra, INC. | $102.67 | 2022 | |
| Contego Medical, INC | $102.50 | 2025 | |
| Inari Medical, INC. | $97.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $93.72 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $91.90 | 2019-2024 | Lokelma |
| Cardiovascular Systems INC. | $59.54 | 2019-2022 | |
| Shockwave Medical, INC | $57.82 | 2025 | |
| Edwards Lifesciences Corporation | $50.86 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Philips North America LLC | $37.20 | 2024 | (6571) Eagle Eye |
| Teleflex LLC | $34.14 | 2019 | |
| Stryker Corporation | $21.03 | 2025 | Flowtriever |
| Merck Sharp & Dohme LLC | $19.81 | 2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.17 | 2025 | Lifevest |
| Chiesi USA, INC. | $12.36 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raed Al-Dallow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.